These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12500235)

  • 21. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
    Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
    Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of recombinant human erythropoietin treatment on the anemia of predialysis patients].
    Furukawa A; Numata A; Imagawa A; Kaifu Y; Sumikura T; Miyake H; Obayashi S; Nakazora H; Hirohata M; Miki S
    Nihon Jinzo Gakkai Shi; 1992 Jun; 34(6):693-700. PubMed ID: 1479709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35).
    Hebert LA; Birmingham DJ; Dillon JJ; Cosio FG; Shen XP
    J Am Soc Nephrol; 1994 Apr; 4(10):1786-91. PubMed ID: 8068876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-expression of the complement regulatory proteins human DAF and CD59 with an IRES-mediated dicistronic mammalian vector enhances their cell protective effects.
    Xu L; Shao H; Wu W; Cao Z; Zhao Z; Liu H; Jiang D; Mao X; Li W
    Int J Mol Med; 2005 Sep; 16(3):409-14. PubMed ID: 16077947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy.
    Park J; Gage BF; Vijayan A
    Am J Kidney Dis; 2005 Nov; 46(5):791-8. PubMed ID: 16253718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of individual complement regulators in the brain and choroid plexus.
    Singhrao SK; Neal JW; Rushmere NK; Morgan BP; Gasque P
    Lab Invest; 1999 Oct; 79(10):1247-59. PubMed ID: 10532588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of complement system regulatory molecules in the endometrium of normal ovulatory and hyperstimulated women correlate with menstrual cycle phase.
    Nogawa Fonzar-Marana RR; Ferriani RA; Soares SG; Cavalcante-Neto FF; Teixeira JE; Barbosa JE
    Fertil Steril; 2006 Sep; 86(3):758-61. PubMed ID: 16831436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure.
    Pereira R; Costa E; Gonçalves M; Miranda V; do Sameiro Faria M; Quintanilha A; Belo L; Lima M; Santos-Silva A
    Hemodial Int; 2010 Jul; 14(3):295-301. PubMed ID: 20649681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients.
    Alegretti AP; Mucenic T; Merzoni J; Faulhaber GA; Silla LM; Xavier RM
    Cell Immunol; 2010; 265(2):127-32. PubMed ID: 20727519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis.
    Makidono C; Mizuno M; Nasu J; Hiraoka S; Okada H; Yamamoto K; Fujita T; Shiratori Y
    J Lab Clin Med; 2004 Mar; 143(3):152-8. PubMed ID: 15007304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
    Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
    Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA).
    Arora M; Kumar A; Das SN; Srivastava LM
    Clin Exp Immunol; 1998 Jan; 111(1):102-6. PubMed ID: 9472668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement regulatory proteins and autoimmunity.
    Kawano M
    Arch Immunol Ther Exp (Warsz); 2000; 48(5):367-72. PubMed ID: 11140463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin.
    Tuzcu A; Bahceci M; Yilmaz E; Bahceci S; Tuzcu S
    Horm Metab Res; 2004 Oct; 36(10):716-20. PubMed ID: 15523598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.